



LIPS Session 10

Oncology and Theranostics Committee

Tuesday, October 20, 09:45–11:15

Session Title

FDG PET in Theranostics: Friend or Foe?

Chairpersons

Irene Burger (Zurich, Switzerland)

Matteo Bauckneht (Genova, Italy)

Programme

09:45–10:15 **Désirée Deandreis** (Villejuif, France): Advantages and Pitfalls of FDG PET in Thyroid Cancer Theranostics

10:15–10:45 **Riccardo Laudicella** (Messina, Italy): Advantages and Pitfalls of FDG PET in Neuroendocrine Neoplasms Theranostics

10:45–11:15 **Irene Burger** (Zurich, Switzerland): Advantages and Pitfalls of FDG PET in Prostate Cancer Theranostics

Educational Objectives

1. Critically evaluate the role of FDG PET in theranostic pathways across different malignancies.
2. Identify common interpretative pitfalls and limitations of FDG PET in both pre- and post-therapeutic settings, including patient selection and response assessment.
3. Discuss clinical scenarios in which FDG PET provides complementary or conflicting information compared to target-specific imaging, with a focus on optimising decision-making in theranostics.

Summary

This session provides a critical overview of FDG PET in the evolving field of theranostics, exploring its advantages and limitations across thyroid cancer, neuroendocrine neoplasms, and prostate cancer. It addresses patient selection, detection of tumour heterogeneity, and treatment response assessment, with attention to interpretative pitfalls and discordant findings between FDG and target-specific imaging. Through dedicated discussion time, participants will develop a more informed and nuanced approach to using FDG PET in theranostic practice.

Key Words

FDG; Theranostics; Patient Selection; Response Assessment; Tumour Heterogeneity; Thyroid Cancer; Neuroendocrine Neoplasms; Prostate Cancer; Pitfalls